Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

• Main Authors: Elif Sargin Altunok, Murat Sayan, Sila Akhan, Bilgehan Aygen, Orhan Yildiz, Suda Tekin Koruk, Resit Mistik, Nese Demirturk, Onur Ural, Şükran Kose, Aynur Aynioglu, Fatime Korkmaz, Gülden Ersoz, Nazan Tuna, Celal Ayaz, Faruk Karakecili, Derya Keten, Dilara Inan, Saadet Yazici, Safiye Koculu, Taner Yildirmak
• Format: Article
• Language: English
• Published: Elsevier 2016-09-01
• Series: International Journal of Infectious Diseases
• Subjects: Baseline resistance; hepatitis C virus; mutation; protease inhibitors
• Online Access: http://www.sciencedirect.com/science/article/pii/S1201971216311109

Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals. Materials and methods: 178 antiviral-naïve patients infected with HCV genotype 1 were selected from 27 clinical centers of various geographical regions in Turkey and included in the current study. The basal NS3 Pls resistance mutations of these patients were analyzed. Results: In 33 (18.5%) of the patients included in the study, at least one mutation pattern that can cause drug resistance was identified. The most frequently detected mutation pattern was T54S while R109K was the second most frequently detected. Following a more general examination of the patients studied, telaprevir (TVR) resistance in 27 patients (15.2%), boceprevir (BOC) resistance in 26 (14.6%) patients, simeprevir (SMV) resistance in 11 (6.2%) patients and faldaprevir resistance in 13 (7.3%) patients were detected. Our investigation also revealed that rebound developed in the presence of a Q80K mutation and amongst two V55A mutations following treatment with TVR, while no response to treatment was detected in a patient with a R55K mutation. Conclusion: We are of the opinion that drug resistance analyses can be beneficial and necessary in revealing which variants are responsible for pre-treatment natural resistance and which mutations are responsible for the viral breakthrough that may develop during the treatment.